comparison role of surfactant(curosurf) and surfactant(curosurf) with fluticasone in infant with Hayline membrane disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138808031378N8

Enrollment

Registered

2011-08-27

Start date

2011-06-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment hyaline membrane disease. Respiratory distress of newborn

Interventions

Intervention 1: surfactant. Intervention 2: surfactant and with fluticasone.

Treatment - Drugs

surfactant

surfactant and with fluticasone

Eligibility

Sex/Gender

All

Age

1 Years to 28 Years

Inclusion criteria

Inclusion criteria: Inclusion: Neonates with more than 1200 g weight who have HMD. Exclusion: Neonate with Asphyxia, CHD, abnormal feature (chromosomal abnormality), renal electrolyte disorders and diaphragmatic hernia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cyanosis. Timepoint: instandly, probably until recovery. Method of measurement: clinical- labratory.;Oxygenatio improvement. Timepoint: Continues until recovery. Method of measurement: clinical- labratory.;Respiration. Timepoint: instandly until recovery. Method of measurement: clinical.	—

Secondary

Measure	Time frame
Ventilation. Timepoint: Continues. Method of measurement: day.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ahmadshah Farhat

Neonatal Research Center

farhata@mums.ac.ir+98 51 1852 1121

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026